Kylie  O'Keefe net worth and biography

Kylie O'Keefe Biography and Net Worth

Chief Customer and Strategy Officer of uniQure

Kylie O’Keefe joined uniQure as Chief Customer and Strategy Officer in June 2025. In this role, she leads the the development and execution of uniQure’s global commercialization strategy. Her responsibilities include all commercial functions and medical affairs. 

Ms. O’Keefe is an accomplished business leader with broad biopharmaceutical experience and a proven track record in rare diseases and gene therapy. Most recently, she served as Chief Commercial Officer at PTC Therapeutics, where she led global commercial strategy, operations and portfolio management for multiple rare neurology and metabolic commercial products across more than 50 countries. During her tenure, Ms. O’Keefe led several strategically significant commercial launches and supported corporate strategy and pipeline development for both small molecules and gene therapies including Upstaza™ (AADC deficiency). She also directed the development and execution of reimbursement strategies, including payer engagement and health economic assessments, and led business development and investor relations. Earlier in her career, Ms. O’Keefe held key roles at LEO Pharma where she launched a portfolio of pharmaceutical products in more than 30 countries. 

Ms. O’Keefe holds a Bachelor’s degree in Biotechnology Innovation from Queensland University of Technology in Brisbane, Australia and a Graduate diploma in Managing Medical Product Innovation from Copenhagen Business School in Frederiksberg, Denmark.

What is Kylie O'Keefe's net worth?

The estimated net worth of Kylie O'Keefe is at least $3.03 million as of June 11th, 2026. Ms. O'Keefe owns 108,864 shares of uniQure stock worth more than $3,034,040 as of June 16th. This net worth evaluation does not reflect any other investments that Ms. O'Keefe may own. Learn More about Kylie O'Keefe's net worth.

How do I contact Kylie O'Keefe?

The corporate mailing address for Ms. O'Keefe and other uniQure executives is PAASHEUVELWEG 25A, AMSTERDAM P7, 1105 BP. uniQure can also be reached via phone at (120) 240-6000 and via email at investors@uniqure. Learn More on Kylie O'Keefe's contact information.

Has Kylie O'Keefe been buying or selling shares of uniQure?

During the last ninety days, Kylie O'Keefe has sold $431,228.16 in uniQure stock. Most recently, Kylie O'keefe sold 15,936 shares of the business's stock in a transaction on Thursday, June 11th. The shares were sold at an average price of $27.06, for a transaction totalling $431,228.16. Following the completion of the sale, the insider now directly owns 108,864 shares of the company's stock, valued at $2,945,859.84. Learn More on Kylie O'Keefe's trading history.

Who are uniQure's active insiders?

uniQure's insider roster includes Walid Abi-Saab (Insider), Madhavan Balachandran (Director), Pierre Caloz (COO), Ricardo Dolmetsch (Insider), Robert Gut (Director), Rachelle Jacques (Director), Matthew Kapusta (CEO), Jack Kaye (Director), Christian Klemt (CFO), Alexander Kuta, III (VP), David Meek (Director), Kylie O'Keefe (Chief Customer and Strategy Officer), Leonard Post (Director), Jeannette Potts (Insider), and Jeremy Springhorn (Director). Learn More on uniQure's active insiders.

Are insiders buying or selling shares of uniQure?

In the last twelve months, insiders at the biotechnology company sold shares 33 times. They sold a total of 503,920 shares worth more than $16,445,021.99. The most recent insider tranaction occured on June, 11th when Director Robert Gut sold 2,726 shares worth more than $73,765.56. Insiders at uniQure own 4.7% of the company. Learn More about insider trades at uniQure.

Information on this page was last updated on 6/11/2026.

Kylie O'Keefe Insider Trading History at uniQure

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
6/11/2026Sell15,936$27.06$431,228.16108,864View SEC Filing Icon  
See Full Table

Kylie O'Keefe Buying and Selling Activity at uniQure

This chart shows Kylie O'keefe's buying and selling at uniQure by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

uniQure Company Overview

uniQure logo
uniQure N.V. develops treatments for patients suffering from rare and other devastating diseases. It offers HEMGENIX that has completed Phase III HOPE-B pivotal trial for the treatment of hemophilia B. The company also develops AMT-130, a gene therapy that is in Phase I/II clinical study for the treatment of Huntington's disease. In addition, it is developing AMT-162, which is in preclinical trial for the treatment of superoxide dismutase 1- amyotrophic lateral sclerosis; AMT-260 that is in preclinical trial to treat temporal lobe epilepsy; AMT-191, which is in preclinical trial for the treatment of fabry disease; AMT-161 that is in preclinical trial to treat amyotrophic lateral sclerosis caused by mutations; AMT-240, which is in preclinical trial to for the treatment of autosomal dominant Alzheimer's disease; and AMT-210 that is in preclinical trial to treat Parkinson's disease. The company was founded in 1998 and is headquartered in Amsterdam, the Netherlands.
Read More

Today's Range

Now: $26.95
Low: $26.66
High: $27.90

50 Day Range

MA: $22.74
Low: $15.38
High: $29.88

2 Week Range

Now: $26.95
Low: $8.73
High: $71.50

Volume

177,335 shs

Average Volume

2,566,350 shs

Market Capitalization

$1.70 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.98